Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash, cash equivalents, and marketable securities totaled $23.2 million [19] - Total operating expenses for Q1 2025 were $12.9 million, resulting in a net loss of $12.8 million [19] Business Line Data and Key Metrics Changes - The company is focused on the NDA submission for cytisinicline, which is expected to be submitted in June 2025 [6][12] - The ORCA-OL open label study has over 100 patients with one year of exposure to cytisinicline, demonstrating strong tolerability [10][14] Market Data and Key Metrics Changes - In the U.S., over 29 million adults smoke cigarettes, and 11 million vape, with more than half wanting to quit but fewer than 10% succeeding due to inadequate tools [7] - Cytisinicline is positioned to be the first new nicotine dependence drug in nearly 20 years, addressing a significant unmet need in the market [8][17] Company Strategy and Development Direction - The primary focus is on treating nicotine dependence and addressing comorbidities associated with smoking, such as COPD [21][22] - The company aims to build a foundation for long-term growth and create lasting value for stockholders through prudent cash management and resource allocation [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the NDA submission process and the potential impact of cytisinicline on public health [6][66] - The company anticipates a 12-month timeline for NDA approval following submission, with a potential commercial launch in 2026 [20][66] Other Important Information - The ORCA-three clinical trial results were published in JAMA Internal Medicine, reaffirming cytisinicline's efficacy and tolerability [15][16] - The company convened a Scientific Advisory Board meeting with experts in nicotine and tobacco cessation research, highlighting the excitement surrounding cytisinicline [15][31] Q&A Session Summary Question: How long before we see the full safety data from the long-term study? - The full safety data will be compiled after the NDA submission and presented at a conference later this year or next year [27] Question: What were some key takeaways from the SAB meeting? - The SAB meeting discussed the applications of cytisinicline treatment and the enthusiasm of key opinion leaders regarding its efficacy and tolerability [29][31] Question: What are the plans for pre-commercial efforts to increase awareness of cytisinicline? - The company is focusing on awareness, availability, and access, ensuring the drug is ready for sale and working on pricing and payer strategies [35][36] Question: What is the status of any partnership discussions for non-dilutive capital? - The company is specifying what it wants from potential partnerships, particularly in the COPD space, and is in discussions with several candidates [41][43] Question: Have there been any changes in interactions with the FDA? - There have been no significant changes; interactions have remained responsive as the NDA submission approaches [47] Question: How are pricing discussions with payers going? - Initial conversations have occurred, but strong perspectives will emerge once pricing is set and further exchanges take place [52] Question: Will the company rely on external partners for commercialization? - The company will heavily rely on agency partners to implement its strategy and build a digital launch roadmap [59]